Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin and Hesperidin in Rheumatoid Arthritis
NCT05756179Phase 3Recruiting
- Sponsor
- Alexandria University
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of diosmin and hesperidin in rheumatoid arthritis (RA), sponsored by Alexandria University. Primary endpoints: Anti-inflammatory Effect at 3 months and Disease activity at 3 months. Started Jul 2023; status: recruiting.
02
Drugs
diosminhesperidin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05756179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756179.